UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~November 1612, 2025

________________________________________

Connect Biopharma Holdings Limited

(Exact name of Registrant as Specified in Its Charter)

________________________________________



Cayman Islands	001-40212	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

	3580 Carmel Mountain Road, Suite 200
	San Diego, California	92130
	(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (877) 245-2787

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary Shares, par value $0.000174 per share

CNTB

The Nasdaq Global Market

Ordinary Shares, par value $0.000174 per Share

CNTB

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

~~Barry~~On D.November ~~Quart~~12, ~~Pharm.D.~~2025, ~~Chief Executive Officer and Director of~~ Connect Biopharma Holdings Limited (the “Company”), ~~purchased~~issued a ~~total~~press ofrelease ~~224,034~~announcing ~~shares~~its offinancial results for the ~~Company~~three inand anine ~~series~~months ended September 30, 2025. A copy of ~~transactions~~the ~~occurring~~press ~~between~~release ~~September~~is ~~2024~~attached hereto as Exhibit 99.1 and ~~September~~is ~~2025~~incorporated herein by reference.

~~David~~In ~~Szekeres,~~accordance ~~President~~with General Instruction B.2 of Form 8-K, the ~~Company~~information in this Item 2.02, ~~purchased~~including athe ~~total~~attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of ~~215~~Section 18 of the Securities Exchange Act of 1934,~~739~~ ~~shares~~as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company inunder athe ~~series~~Securities Act of ~~transactions~~1933, ~~occurring~~as ~~between~~amended, ~~November~~or ~~2024~~the ~~and~~Exchange ~~September~~Act, ~~2025~~whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

~~All purchases described in this~~ Item 79.01 ~~were~~Financial ~~made~~Statements inand ~~compliance with the Company’s Insider Trading Compliance Policy, as in effect at the applicable times~~Exhibits.

The information in Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (~~the “Exchange Act”~~d), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no obligation to publicly update any information furnished in this Item 7.01, whether because of future events or otherwise.Exhibits


Exhibit No.						Description
99.1						Press Release of the Company, dated November 12 , 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CONNECT BIOPHARMA HOLDINGS LIMITED
Date:	~~September~~November 1612, 2025	By:	/s/ ~~David~~Lisa ~~Szekeres~~Peraza
		Name:	~~David~~Lisa ~~Szekeres~~Peraza
		Title:	Senior Vice President, Finance

Filing Compare · Connect Biopharma Holdings Ltd